Adicet Bio, Inc. ACET

ACET Company Overview

Adicet Bio, Inc. is a clinical-stage biotechnology company focused on the development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company operates within the biotechnology and cell therapy industries, with its core strategy centered on engineering off-the-shelf immune cell therapies designed to overcome limitations associated with autologous CAR-T approaches. Adicet’s primary revenue activity has historically consisted of collaboration revenue and financing activities, as the company does not currently market approved commercial products. Its lead programs target autoimmune indications, including lupus nephritis and systemic sclerosis, alongside earlier-stage oncology applications.

The company was founded in 2014 and evolved through advances in gamma delta T cell engineering and induced pluripotent stem cell-related research. Adicet became publicly traded through a merger transaction involving resTORbio, Inc., after which the combined company adopted the Adicet Bio name and ticker symbol ACET. The company’s strategic positioning is based on its proprietary gamma delta T cell platform, which is intended to provide scalable manufacturing, reduced graft-versus-host disease risk, and the ability to deliver standardized allogeneic cell therapies to broader patient populations.